UNSPSC 51111717: Trastuzumab

This classification denotes a monoclonal antibody with the molecular formula C6470H10012N1726O2013S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P188ANX8CK, more generally known as trastuzumab. European Medicines Agency schedules trastuzumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12612MIG. The term TRASTUZUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 2 1999, list 40.

UNSPSC 51111717 Trastuzumab is a Commodity code covering the procurement of this specific monoclonal antibody therapeutic used in oncology treatment. State and local governments purchase trastuzumab primarily through their pharmacy benefit programs, Medicaid agencies, and state employee health plans. The recent activity under this code reflects state health agencies' effort to reshape how they acquire high-cost specialty pharmaceuticals — moving away from traditional pharmacy benefit manager (PBM) and group purchasing organization (GPO) intermediaries toward direct manufacturer relationships to improve cost management and prescription fulfillment efficiency. The Texas Health and Human Services Commission is the primary recent issuing body, representing state Medicaid and employee health plan procurement authority.

Texas HHS issued a Request for Information (RFI) No. HHS0017013 on March 27, 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI seeks detailed vendor responses on experience with direct contracting for self-insured employers and health plans in private and government sectors within the past two years, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. No formal evaluation criteria, site visit requirements, or award values are specified in this preliminary information-gathering phase; the RFI is designed to inform Texas HHS's future procurement strategy and contracting approach before issuing a formal Request for Proposal with established financial and temporal parameters. The absence of additional recent opportunities under this code suggests limited activity in state and local trastuzumab procurement outside Texas's direct-to-manufacturer initiative at present.